Cargando…

Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study

INTRODUCTION: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for such patients. Our study aimed to evaluate whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kogure, Yoshihito, Kada, Akiko, Hashimoto, Hiroya, Atagi, Shinji, Takiguchi, Yuichi, Saka, Hideo, Ebi, Noriyuki, Inoue, Akira, Kurata, Takayasu, Fujita, Yuka, Nishii, Yoichi, Itani, Hidetoshi, Endo, Takeo, Saito, Akiko M., Shibayama, Takuo, Yamamoto, Nobuyuki, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250914/ https://www.ncbi.nlm.nih.gov/pubmed/37304652 http://dx.doi.org/10.1016/j.jtocrr.2023.100514

Ejemplares similares

An open-label, single-arm study of CRYO2 for tissue removal at the site of central airway obstruction or stenosis: study protocol
por: Saka, Hideo, et al.
Publicado: (2018)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
por: Fukui, Tomoya, et al.
Publicado: (2022)

Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol
por: Nakagawa, Taku, et al.
Publicado: (2019)

Multicentre, open-label, randomised controlled clinical trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild-to-moderate stenotic lesions with high-risk plaques in coronary arteries: study protocol
por: Matsuda, Morihiro, et al.
Publicado: (2019)

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
por: Yoh, Kiyotaka, et al.
Publicado: (2021)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hayashi, Hidetoshi, et al.
Publicado: (2011)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020)

Status and Future Perspectives of Utilizing Big Data in Neurosurgical and Stroke Research
por: NISHIMURA, Ataru, et al.
Publicado: (2016)

Public awareness of the need to call emergency medical services following the onset of acute myocardial infarction and associated factors in Japan
por: Yonemoto, Naohiro, et al.
Publicado: (2018)

Cross-talk between cancer cells and their neighbors via miRNA in extracellular vesicles: an emerging player in cancer metastasis
por: Kogure, Akiko, et al.
Publicado: (2019)

Extracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials
por: Kogure, Akiko, et al.
Publicado: (2020)

Patient Factors Influencing Intraocular Penetration of Brimonidine-Related Eye Drops in Adults: A Post Hoc Pooled Analysis
por: Kunikane, Eriko, et al.
Publicado: (2023)

Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial
por: Nagai, Hirokazu, et al.
Publicado: (2017)

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol
por: Sekimizu, Masahiro, et al.
Publicado: (2018)

Rebuilding Social Capital through Osekkai Conferences in Rural Communities: A Social Network Analysis
por: Ohta, Ryuichi, et al.
Publicado: (2022)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020)

Reply to “Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?”
por: Matsuura, Hiroaki, et al.
Publicado: (2021)

The Association between Oxytocin and Social Capital
por: Fujiwara, Takeo, et al.
Publicado: (2012)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

Development and characterization of an anti-rituximab monoclonal antibody panel
por: Tada, Minoru, et al.
Publicado: (2018)

Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design
por: Ogihara, Takuo, et al.
Publicado: (2023)

Safety and efficacy of endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) for patients aged 80 years and older
por: Niwa, Hideyuki, et al.
Publicado: (2022)

Thin bronchoscopic cryobiopsy using a nasobronchial tube
por: Oki, Masahide, et al.
Publicado: (2022)

Associations of social capital and health at a city with high aging rate and low population density
por: Watanabe, Jun-ichiro, et al.
Publicado: (2021)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
por: Ohe, Yuichiro, et al.
Publicado: (2018)

Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan
por: Matsuura, Hiroaki, et al.
Publicado: (2020)

Acute eosinophilic pneumonia caused by nicotine‐free vaping in an adolescent patient: A case report
por: Takigawa, Yuki, et al.
Publicado: (2022)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan
por: Koh, Katsuyoshi, et al.
Publicado: (2018)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
por: Kogure, Yoshihito, et al.
Publicado: (2015)

Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations
por: Shibata, Kai, et al.
Publicado: (2021)

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
por: Okamoto, Isamu, et al.
Publicado: (2014)

Impact of individual and neighborhood social capital on the physical and mental health of pregnant women: the Japan Environment and Children’s Study (JECS)
por: Morozumi, Ryoko, et al.
Publicado: (2020)

Clinical prediction scores and early anticoagulation therapy for new-onset atrial fibrillation in critical illness: a post-hoc analysis
por: Sakuraya, Masaaki, et al.
Publicado: (2021)

Development of a Cell-Based Assay Measuring the Activation of FcγRIIa for the Characterization of Therapeutic Monoclonal Antibodies
por: Tada, Minoru, et al.
Publicado: (2014)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
por: Takada, Kenji, et al.
Publicado: (2021)

Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report
por: Kuribayashi, Tadahiro, et al.
Publicado: (2021)

Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
por: Takigawa, Yuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cn0fdkkjjfcc0ff24c28vamvu9